A new systematic review and simulation study discussed cost estimators. Simple mean has an upward bias from 12% to 113%. To reduce bias, use volume-weighted mean, calibration, or regression estimators.
The Expanded Program on Immunization Costing project (EPIC), led by Dr. Stephen Resch, aims to understand the cost and cost drivers of delivering immunization programs in low- and middle- income countries. Learn more about job opening here
Analyses estimating program costs collected on a subsample of facilities are subject to statistical uncertainty, often quantified via standard errors and/or 95% confidence intervals. This recent publication elaborates methods to reduce statistical uncertainty.
This short report revealed community members' demographics, location and area of work, the projects they work on, the identified public resource, and current needs in methodological guide.
In the October 2017 Newsletter Issue, Dr. Brenzel thanks and welcomes the members of the Immunization Economics Community of Practice. Read her welcome letter here.
Your participation in this survey is crucial in helping us develop the evidence and resources to further the field of Immunization Economics. This survey should take around 20 minutes to complete. Thank you very much for your support. Take the survey here
Health Policy & Planning podcast discusses the importance in understanding detailed cost structure, its relationship with efficiency, and implications for health policy and future planning in immunization programs. Listen to podcast here.
Health Policy and Planning blogpost examines how detailed understanding of the cost structure of immunization programs can inform policy. Read more here.
New analyses revealed costs distribution across budget categories and programmatic activities, and investigated variation of the cost structure by country and site characteristics. See more here
Accurate information on the cost and financing of national immunization programs can be lacking. Research and a new website are designed to help governments worldwide manage their immunization programs and plan for the future. See more here
Vaccine Volume 33, Supplement 1, Pages A1-A254 (7 May 2015): Expanding the Evidence Base to Inform Vaccine Introduction: Program Costing and Cost-effectiveness Analyses. See more here
The recent issue published, among others, papers on the return on investment, and the share of government financing of immunization program. The briefing video, audio, agenda, and slides have been posted to Health Affair's website.
PAHO / WHO: Although new vaccines are more costly than traditional ones, they are overwhelmingly cost-effective and should continue to be considered a public health "best buy." See more here.
Performance, productivity and costs of immunization programs - evidence from the EPIC studies. This panel session focuses on the productivity and cost determinants of routine immunization programs. See more here.